Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

September 03, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

September 03, 2019

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.